Systematic Review of Clinical and Economic Evidence for Primary Open-Angle Glaucoma Therapy with Tafluprost vs Travoprost

Table of contents

1. Introduction

laucoma is one of the leading causes of blindness, it is a chronic disease that visual area is reduced permanently because of optic nerve damage.

According to the World Health Organization, total number of patients with glaucoma in the world ranges from 60.5 to 105 million people, and increasing this number is predicted to 80 million. There is significant an increase the role of glaucoma among primary disability causes, the nosological structure increased up to 20% in the last decade. According to the statistics of WHO, more than 28 million people in the world faced to the blindness, it means almost one in five has lost sight cause of glaucoma.

In majority of patients (about 86%) suffer from glaucoma for a long time, the disease passes into a more severe stage. In this regard, this disease is not only purely medical issue, but also it is social problems.

The research questions were asked in discussions with healthcare providers, clinical professionals, and other healthcare stakeholders.

The aim of the study was to conduct a systematic review of the clinical and economic evidence for the therapy of primary open-angle glaucoma (POAG) with Tafluprost vsTravoprost.

2. II.

3. Materials and Methods

A literature search was performed on PubMed interface and used for the MEDLINE database, in addition, the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and NICE were used to search for relevant literature. As an input of medical librarians, search strategy was developed by using appropriate keywords and control variables. In order to obtain relevant information on the prevalence of glaucoma and other important evidence, we searched the gray literature on various health websites. The formulation of the PICO concept is very critical because it facilitates the therapeutic question and directly addresses the relevant issues, defining the key concepts that should be the focus of our economic analysis of health care.

The acronym PICO is presented in the following In order to evaluate clinical outcomes feedback was requested from several associations involved in glaucoma therapy in Tashkent city. We turned to an ophthalmologist, nurses who regularly diagnose glaucoma in patients. The role of the clinical expert was to critique our requests, provide information regarding the patient management algorithm, review the clinical review plan and medical technology assessment.

Economic literature search was conducted to cover studies conducted from inception to the date of the search. PubMed interface was used for the Medline database, and the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and NICE were used to search relevant literature. By input from medical librarians, a search strategy was developed with relevant keywords and control variables, with an economic filter set. In order to obtain relevant information on the current prevalence of glaucoma and other important evidence, we conducted a gray literature search on various health websites.

Titles and abstracts of the papers were carefully reviewed, for those studies that should meet the eligibility criteria, we purchased articles with full content and completed further evaluation for eligibility.

4. III.

5. Results and Discussions

A clinical efficacy literature search identified 434 studies, including those obtained from database searches and additional sources. After removing duplicates and irrelevant studies assessed by title selection, 285 citations remained. Finally, only 2 articles meet the inclusion criteria. To report the studies, we found in systematic reviews, we developed the PRISMA Chart (Preferred Reporting Items for systematic reviews and meta-analyses) (Figure 1). Two single arm cohort studies were selected because they met the inclusion criteria. The first study examined IOP adjustment and visual area imperfection movement over a 3-year period while adjusting Travoprost eye drops monotherapy in patients with POAG [2]. A second cohort study examined the effects of Tafluprost eye drops on IOP changes, visual area progression, safety, and side effects in patients with POAG [3].

We were unable to find studies examining mortality due to glaucoma. In addition, there is no any research conducted to investigate patients with advanced and end-stage glaucoma treated with our interventions. Overall, both Travoprost and Tafluprost were found to be effective interventions for lowering intraocular pressure in patients with POAG. Innoueetal. (2012) in their randomized control trial showed the effectiveness of Travoprosteye drops in reducing IOP, which in the long term was 16.1-36.6%, while the reduction in IOP by 21.9±14.0% with the introduction of Tafluprost in patients with POAG. There have been no reports of visual area impairment due to long-term use of Tafluprost and Travoprost eye drops. Significant differences in average and standard deviation of the model were not observed before and after treatment with follow-up 3 years in both analyzed studies. It can be seen that when comparing the efficacy of the two interventions, Travoprost had a slightly higher efficacy in lowering IOP than Tafluprost among patients with POAG [2,3].

A systematic review identified one study evaluating the economic effectiveness of Travoprost and Tafluprost in the treatment of pre-intervention openangle glaucoma in previously untreated 65-year-old patients.

Intraocular pressure, visual area characteristics, and patient value of drugs are derived from published retrospective clinical reviews and randomized control trials with a follow-up period of 20 years. Average wholesale prices were taken to calculate drug price data for both social and direct eye care costs. As recommended by the Health and Medicine Cost Efficiency Panel, all costs and benefits assessed by the patient were discounted annually at a rate of 3%. The results showed that each anti-intervention drug has demonstrated clinical and economic effectiveness. Travoprost scored 1.92 QALYs (15% improvement in quality of life) over a 20-year period, and Tafluprost scored a slightly higher score of 1.99 QALYs (14.2%

Figure 1. table 1
Note: FShoyusuf F.
Figure 2. Table 1 :
Acronym General definition Acceptance of the model
P Population (patients) Patients over 40 with open-angle glaucoma
Intervention (Intervention -an Tafluprost is a prostaglandin analogue eye drops
I alternative method of treatment used to prevent the progression of open-angle
(relatively new) glaucoma by lowering intraocular pressure(IOP).
Comparator Travoprost is a prostaglandin analogue eye drops
C (Comparator - traditional used to prevent the progression of open-angle
treatment) glaucoma by lowering IOP.
O Outcome efficiency (The result is profitability) of economic Lowering IOP and delaying the progression of glaucoma
Figure 3. Table 2 :
Records identified through database Additional records identified through
Identification searching (n=45) Records after duplicates removed other sources (n = 20)
(n =50)
(n = 50)
Screening Full-text articles assessed for eligibility (n = 10) Full-text articles excluded(n=9): ? Pre-clinical
? Laser therapy
? Abstracts
? Articleisnotrelated to economicefficiency
Included Studies included in reviews (n = 1)
Authors, year Country Purpose of the study Randomized groups Basic mean deviation(MD) Patients(men /women) Average age Years (SD) Result
Inoue, Iwasa, Wakakura and Tomita, 2012 Japan To study the area efficiency. efficiency of long-term Travoprost monotherapy without (BAC) on IOP and visual Mean IOP at switch on 16.8±2.6 mmHg. -5.4±4.7dB :33/43 54.8±13.9 Decreased intraocular pressure (IOP)
Figure 4. Table 3 :
Author s, year Level of IOP reduction Progression field of view
Inoue, Iwasa, Wakakura and When treated with Travoprost 2.8%-13.9%
Tomita (2012) 14.1±2.4 mmHg (Before treatment: 16.8±2.6
Innoue, Tanaka and Tomita When treated with Tafluprost 10.3%-13.8%
(2013) 12.8±2.8 mmHg Art. (before therapy: 15.7±2.2
Figure 5. Table 4 :
Figure 6.
Year 2022
Volume XXII Issue III Version I
D D D D )
Author, year Study type Population Intervention/ Control (Comparator) health outcomes Results Expenses Economic Efficiency Research period Medical Research
Brown 2019 Cost-utility analysis Patients over 40 years of age Tafluprost Travoprost sensitivity analyzes were also performed with upper and 1.99 QALY (17.9%) $1,925 cost/year ICER is missing 3 months a l.92 QALY (17.2%) $944 cost/year Global Journal of
lower IOP limits at 95% confidence intervals. Tafluprost
remained with the best QALY scores among other
A study by Brown et al. (2019) showed that
even though Travoprost is cheaper than Tafluprost,

Appendix A

  1. Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. London: National Collaborating Center for Acute Care. A Heijl . 10.1001/archopht.120.10.1268. Archives of Ophthalmology 2002. 20 January 2020. 2009. Accessed 20 January 2020. 120 (10) p. . (Reduction of Intraocular Pressure and Glaucoma Progression)
  2. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. A Liberati . doi:10.1136/ bmj.b2700. BMJ 2009. 20 January 2020. p. . (jul21 1)
  3. The Impact of Anchor Point on Utilities for 5 Common Ophthalmic Diseases. B S Lee . 10.1016/j.ophtha.2007.06.008. The American Academy of Ophthalmology 2008. 20 January 2020. 115 (5) p. .
  4. The Economic Burden of Major Adult Visual Disorders in the United States. D B Rein . 10.1001/archopht.124.12.1754. Archives of Ophthalmology 2006. Accessed 12 December 2019. 124 (12) p. .
  5. Patient Preference-Based Comparative Effectiveness and Cost-Utility Analysis of the Prostamides for Open-Angle Glaucoma. G C Brown , M M Brown . 10.1089/jop.2018.01145.Nice.[Accessed10 Journal of ocular pharmacology and therapeutics 2019. 2017. January 2020. (Glaucoma: Diagnosis and management. London: National Institute for Health and Care Excellence (UK))
  6. Guidelines for the treatment of glaucoma of the International Council of Ophthalmology (ICO). International Council of Ophthalmology 2016. 20 January 2020. (San Francisco: ICO)
  7. Effects of Travoprost treatment for 3 years in patients with normal-tension glaucoma. Iwasa Inoue , Tomita Wakakura . Clinical Ophthalmology 2012. 6 p. .
  8. Effects of Tafluprost treatment for 3 years in patients with normal-tension glaucoma. Iwasa Inoue , Tomita . Clinical Ophthalmology 2013. 7 p. .
  9. Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery. P Lichter . 10.1016/s0161-6420(01)00873-9. Ophthalmology 2001. January 2020. 108 (11) p. .
  10. Does the type of treatment have an influence on utility values in a glaucoma population. R Paletta Guedes , V Paletta Guedes , S Freitas , A Chaoubah . 10.2147/opth.s92653. Clinical Ophthalmology 2015. 20 January 2020. p. .
  11. Economic evaluation and modeling of healthcare technologies, S Dzhalalov , Ch , D Dzhalalova , Kh , M Kran , D Khoch . p. 59. (Tashkent. 2020)
  12. The role of systematic review and meta-analysis in the evaluation of technologies in health care. S Jalalov , Ch , D Jalalova , Kh , D S Khoch . Medical Technology: Evaluation and Choice 2012. (3) p. .
  13. Conceptualization of a model for medical technology assessment. Medical technology assessment and selection, S Jalalov , Ch , D Jalalova , Kh , D S Khoch . 2014. p. .
  14. Uzbekistan. World Health Organization. World Health Organization 2016. Accessed 20 January 2020.
© 2022 Global Journals
© 2022 Global Journals Systematic Review of Clinical and Economic Evidence for Primary Open-Angle Glaucoma Therapy with Tafluprost vs Travoprost
Date: 2022 1970-01-01